Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 20 
Presentar resultados
Seleccionar todas
1. Cita con resumen
2.Tiene citas relacionadas Cita con resumen
Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100198]
3.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin: even the score does not add up. JAMA Intern Med 2016;176:439-42. [Ref.ID 100197]
4. Cita con resumen
Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, Lehrfeld K, Lee L, Kim MJ, Slagle AF, Beitz J. FDA approval of flibanserin — Treating hypoactive sexual desire disorder. N Engl J Med 2016;374:101-4. [Ref.ID 100089]
5.Tiene citas relacionadas Cita con resumen
Jaspers L, Feys F, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women. A systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100072]
6.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]
7. Cita con resumen
Anónimo. Valeant “predatorily priced” female libido drug, investors claim. DIA Daily 2016:1. [Ref.ID 100042]
8. Cita con resumen
Anónimo. Flibanserin (Addyi) for hypoactive sexual desire disorder. Med Lett Drugs Ther 2015;57:133-5. [Ref.ID 99654]
9. Cita con resumen
Gellad WF, Flynn KE, Alexander C. Evaluation of flibanserin: science and advocacy at the FDA. JAMA 2015;314:869-70. [Ref.ID 99515]
10. Cita con resumen
Pozzi M. Valeant compra la compañía del "Viagra femenino". El País 2015:21. [Ref.ID 99415]
11. Cita con resumen
Herman AO. FDA approves drug for hypoactive sexual desire disorder in women. Journal Watch 2015:1. [Ref.ID 99407]
12. Cita con resumen
Young K. FDA advisers back approval of first drug for female sexual dysfunction. Journal Watch 2015:1. [Ref.ID 99241]
13.Tiene citas relacionadas Cita con resumen
Roehr B. FDA committee recommends approval for “female Viagra”. BMJ 2015;350:h3097. [Ref.ID 99189]
14. Cita con resumen
Moynihan R. Evening the score on sex drugs: feminist movement or marketing masquerade?. BMJ 2014;349:g6246. [Ref.ID 98287]
16.Tiene citas relacionadas
Goldbeck-Wood S. Female sexual dysfunction is a real but complex problem. BMJ 2010;341:701. [Ref.ID 89455]
17.Tiene citas relacionadas Cita con resumen
Moynihan R. Merging of marketing and medical science. BMJ 2010;341:698-700. [Ref.ID 89454]
18.
Moynihan R. FDA panel to assess drug for low sexual desire in women. BMJ 2010;340:1161. [Ref.ID 88626]
19. Cita con resumen
Moynihan R. Psychiatrists aim to redefine female sexual dysfunction. BMJ 2010;340:335. [Ref.ID 87827]
20. Cita con resumen
Anónimo. Drugs for female sexual dysfunction. Med Lett Drugs Ther 2007;49:33-4. [Ref.ID 80135]
Seleccionar todas
 
 1 a 20 de 20